Exosome-based therapy for atopic dermatitis: translational status, clinical evidence, and regulatory reality

Objectives To evaluate the translational rationale, published clinical evidence, investigational development, and regulatory considerations for extracellular vesicle (EV; frequently described as exosome) therapy in atopic dermatitis (AD).Methods We conducted a narrative review of PubMed, Web of Science, and Google Scholar from inception through August 2026, supplemented by reference screening and ClinicalTrials.gov searches. Experimental studies, human reports, and investigational trial records were assessed separately.Results Thirty experimental studies reported improvements in barrier-related or inflammatory outcomes in cellular and animal models, although EV sources, characterization, dosing, and delivery differed substantially. Published human evidence was limited to three uncontrolled reports (42 patients): 22 with dupilumab-associated facial redness and 20 with facial AD. No published randomized controlled efficacy trial of EV therapy for human AD was identified. Subcutaneous BxC-I17e has entered phase 1 investigation, but publicly available efficacy findings remain limited to conference reporting. Major limitations include incomplete EV characterization, lack of validated potency assays, uncertain topical penetration, and insufficient long-term safety data. No exosome product is approved by the US Food and Drug Administration.Conclusions Although EV preparations show preclinical promise, evidence is insufficient to recommend their routine use for AD. Product-specific, randomized controlled trials with standardized manufacturing and robust safety assessments are required.

Authors

Institutions

Publication Details

Journal
Journal of Dermatological Treatment
Published
2026-11-21
DOI
https://doi.org/10.1080/09546634.2026.2761113
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exosome-based therapy for atopic dermatitis: translational status, clinical evidence, and regulatory reality

Almuntsrbellah M. Almudimeegh, Naif Jameel Alshehri, Khalid Nabil Nagshabandi
Journal of Dermatological Treatment
Extracellular vesicles in disease
article

Exosome-based therapy for atopic dermatitis: translational status, clinical evidence, and regulatory reality

Almuntsrbellah M. Almudimeegh, Naif Jameel Alshehri, Khalid Nabil Nagshabandi
article en

Abstract

Objectives To evaluate the translational rationale, published clinical evidence, investigational development, and regulatory considerations for extracellular vesicle (EV; frequently described as exosome) therapy in atopic dermatitis (AD).Methods We conducted a narrative review of PubMed, Web of Science, and Google Scholar from inception through August 2026, supplemented by reference screening and ClinicalTrials.gov searches. Experimental studies, human reports, and investigational trial records were assessed separately.Results Thirty experimental studies reported improvements in barrier-related or inflammatory outcomes in cellular and animal models, although EV sources, characterization, dosing, and delivery differed substantially. Published human evidence was limited to three uncontrolled reports (42 patients): 22 with dupilumab-associated facial redness and 20 with facial AD. No published randomized controlled efficacy trial of EV therapy for human AD was identified. Subcutaneous BxC-I17e has entered phase 1 investigation, but publicly available efficacy findings remain limited to conference reporting. Major limitations include incomplete EV characterization, lack of validated potency assays, uncertain topical penetration, and insufficient long-term safety data. No exosome product is approved by the US Food and Drug Administration.Conclusions Although EV preparations show preclinical promise, evidence is insufficient to recommend their routine use for AD. Product-specific, randomized controlled trials with standardized manufacturing and robust safety assessments are required.

Journal of Dermatological TreatmentVol. 37(1)
King Saud University (SA)
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon